Narcan, a brand-name prescription nasal spray effective at reversing opioid overdoses, can be sold over the counter, the Food and Drug Administration decided today. Narcan’s active agent is naloxone.
A small pilot study suggests that the technology meets the demand for a clinician to witness a patient’s daily dose.
Researchers will explore the ability of Black and Latinx patients to get the less-stigmatized treatment drug, buprenorphine.
Offering directly observed therapy with a video smartphone app did not improve buprenorphine engagement or outcomes, study finds.
